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Abstract
Anxiety related to pediatric inflammatory bowel disease (IBD) is a common comorbidity; yet, this con-
struct is understudied because of lack of available valid measurement. Objective The present study
will report the preliminary validation of the 20-item IBD-Specific Anxiety Scale (IBD-SAS) in a large,
geographically diverse sample of adolescents aged 12–18 years with IBD. Method A total of 281
adolescents, ages 12–18 (M ¼ 14.8, SD ¼ 1.78; 51% male), completed the IBD-SAS along with meas-
ures of IBD-related quality of life, anxiety, depressive symptoms, and disease activity. Factor structure
was assessed using exploratory and confirmatory factor analyses (EFA and CFA). Results EFA
(Sample 1; n ¼ 141) yielded one-, two-, three- and four-factor models. The CFA (Sample 2; n ¼ 140)
demonstrated that a four-factor model was superior to three- and two-factor model for the amended
scale. In total, the IBD-SAS showed excellent internal consistency (Cronbach’s a¼ .95) and was most
strongly associated with health-related quality of life. Moderate to strong associations were observed
between IBD-SAS and general measures of anxiety and depressive symptoms, and IBD disease activ-
ity providing additional support that health-specific anxiety is a valid and distinct construct.
Conclusions Based on the results of this study, the IBD-SAS displayed adequate psychometric prop-
erties and can meaningfully contribute to the assessment of IBD-specific anxiety in adolescents diag-
nosed with IBD, thus filling an empirical and clinical need in this population.
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Pediatric inflammatory bowel disease (IBD) is a
chronic medical condition with no known cure. The
onset of IBD is characterized by an acute phase sur-
rounding the initial diagnosis of the illness, which can
require invasive medical procedures (e.g., colonos-
copy) and, in some cases, hospitalization. Disease
symptoms vary, depending on the severity of inflam-
mation and where it occurs on the gastrointestinal
tract, and presence of extra-intestinal symptoms, but
the most common symptoms include bowel movement
urgency, bloody stool, abdominal pain, and fatigue.
Symptoms can range from mild to severe and are char-
acterized by an unpredictable course with periods of
active illness followed by periods of remission.
IBD and its treatment present youth and their parents
with significant challenges and, for some, is a source of
chronic stress that can contribute to emotional and be-
havioral problems (Mackner, Crandall, & Szigethy,
2006). If undetected or left untreated, these problems
can compromise adherence to treatment regimens
(Jackson, Clatworthy, Robinson, & Horne, 2010) as
well as impact disease processes (Cohen, Janinicke-
Deverts, & Miller, 2007; Segerstrom & Miller, 2004).
To address the emotional burden of this disease, a
number of studies have focused on the identification
and treatment of comorbid psychiatric conditions
such as anxiety and depression as well as general emo-
tional distress (see Graff, Walker, & Bernstein, 2009;
Mikocka-Walus, Knowles, Keefer, & Graff, 2016 ;
Regueiro, Greer, & Szigethy, 2017 for systematic re-
view). Moreover, a recent practice guideline has also
recommended the assessment and treatment of psy-
chosocial health in youth with IBD (Rufo et al., 2012).
Yet, there are no current validated measures for
assessing IBD-specific anxiety. This is problematic,
given that anxiety related to living with and managing
a chronic medical condition may not be detected using
traditional anxiety inventories (Woodward et al.,
2016). Consequently, this lack of measurement likely
precludes the full clinical assessment of anxiety in pe-
diatric patients with IBD.
While it is generally believed that disease-specific
anxiety is common among individuals living with the
disease, studies of this construct are just beginning to
emerge. A study of 294 adults with diagnosed IBD
(Keeton, Mikocka-Walus, & Andrews, 2015) demon-
strated that all participants, but 11, reported signifi-
cant IBD-related concerns despite the majority (74%)
being in remission. Concerns and worries were mea-
sured using one open-ended question, and responses
were then thematically coded. Four themes were iden-
tified; they included concerns related to quality of life
(51%), unpredictability (35%), symptoms (34%), and
treatments (19%). A handful of other qualitative stud-
ies also support the prevalence of IBD-specific distress
related to managing the physical symptoms of IBD
such as bowel movement urgency and fatigue
(Czuber-Dochen, Dibley, Terry, Ream, & Norton,
2013; Dibley & Norton, 2013). These studies point to
the need for more communication with medical pro-
viders to manage symptoms and concerns.
Among pediatric samples, one small qualitative
study suggests that youth diagnosed with IBD may be
particularly susceptible to developing disease-specific
fears because of having to balance uncertain periods
of stable health status (Lynch & Spence, 2008), which
can in turn contribute to a subjective sense of vulnera-
bility (Nicholas et al., 2007). More recent evidence
suggests that psychological interventions for individu-
als with chronic illness and comorbid distress may
only be efficacious when illness-specific perceptions
are addressed (Knoop, van Kessel, & Moss-Morris,
2012; Wiborg, Knoop, Frank, & Bleijenberg, 2012),
highlighting the need to measure and target disease-
related emotional factors.
Little is known about the etiology, impact, or treat-
ment of pediatric IBD-specific anxiety, in part, because
of the lack of definition and instrumentation to measure
this construct; thus, the IBD-Specific Anxiety Scale
(IBD-SAS) was created. There are overlapping features
between IBD-specific anxiety and somatic symptom dis-
order. Somatic symptom disorder is an excessive focus
on one or more somatic symptoms accompanied by
marked distress or functioning impairment. Somatic
symptoms can be related to a medical condition, but the
distress is excessive than what would be expected; IBD-
specific anxiety extends beyond significant focus and
worry about physical symptoms, to include other areas
of concern related disease management and adjustment.
Specifically, IBD-specific anxiety is defined as worry
that is disproportionate to context, or unrealistic overes-
timation of negative outcomes, surrounding the reoccur-
rence and implication of physical symptoms, treatment,
and medical procedures associated with IBD (Casati,
Toner, de Rooy, Drossman, & Maunder, 2000;
Dorrian, Dempster, & Adair, 2009). This anxiety may
be present during disease relapse, as well as in periods
of remission (Reigada et al., 2015).
The initial version of the IBD-SAS (Reigada et al.,
2011) contained 11-items and was developed by a mul-
tidisciplinary team of investigators including experts in
the field of anxiety and pediatric chronic illness, gastro-
enterologists, and families with children with IBD. The
measure was further revised (to the current version) to
include additional areas of disease concern (e.g., wor-
ries pertaining to height, growth, medical treatment re-
sponse, etc.). Revisions were informed by the clinical
knowledge gained through the assessment and treat-
ment of comorbid anxiety disorders in pediatric IBD in
an open pilot (Reigada et al., 2015) and a randomized
controlled trail. While the development of the IBD-SAS
preceded publication of the Journal of Pediatric
Psychology (JPP) guidelines for measure development
(Holmbeck & Devine, 2009), the following strategies,
that overlap with key features of the JPP criteria, were
used to develop the IBD-SAS: (1) clearly establishing a
research and clinical need for the instrument, and (2)
consideration of content validity, which included (i)
creating a well-defined construct with a specified pur-
pose and target population; and (ii) item generation
based on clinical experience, empirical literature, re-
lated instruments, and consultation with experts and
target population.
Early use of this measure has provided preliminary
evidence that items on the IBD-SAS differentiate IBD-
specific anxiety from Diagnostic and Statistical
Manual of Mental Disorders (DSM)-IV anxiety condi-
tions (i.e., social anxiety, generalized anxiety, panic
disorder, and separation anxiety), depressive symp-
toms, and IBD-specific quality of life (Reigada et al.,
2011). Also of note, this study found that elevated
IBD-specific anxiety symptoms, rather than general
anxiety or depressive symptoms, were associated with
greater utilization of medical services and decreased
social functioning among adolescents with IBD. In
other studies, significant reductions in IBD-specific
anxiety, measured by the IBD-SAS, was found imme-
diately following receipt of a 13-week health sensitive
cognitive behavioral treatment (Reigada, et al., 2015)
and 3 months later. This finding provides preliminary
evidence that the IBD-SAS may be sensitive to treat-
ment effects.
The current scale includes 20 questions pertaining to
how often, within the past 2 weeks, youth “worried”
about their IBD symptoms and medical treatment, as
well as their concerns regarding disease impact on school,
social relations, and body image. Items are rated on a six-
point Likert scale ranging from 0 to 5 points (0¼never,
5¼ always) with higher scores relating to more IBD-
specific anxiety. The analyses of the psychometric proper-
ties and factor structure of the IBD-SAS have not previ-
ously been conducted and is the rationale for the present
study. Establishing a psychometrically sound instrument
will provide a mechanism by which IBD-related anxiety
can be identified, and subsequently treated, and allow for
empirical testing of the impact of disease-specific anxiety
on emotional and physical outcomes.
The aim of this study was to evaluate the psycho-
metric properties of the IBD-SAS in a large, geographi-
cally diverse sample of adolescents aged 12–18 years
with IBD, namely, its factor structure, using explor-
atory and confirmatory factor analyses (EFA and
CFA), and internal consistency. We also sought to eval-
uate the external validity of the IBD-SAS by examining
the association between this measure with indices of
IBD-related quality of life and IBD severity. We hy-
pothesized that the IBD-SAS would have the strongest
association with IBD health-related quality of life
(HRQoL). IBD HRQoL assesses subjective perception
of health state and includes several overlapping
domains with IBD-SAS, including disease and bowel
functioning as well as emotional and social functioning
(Mouzas & Pallis, 2000). We predicted a low to mod-
erate correlation between IBD-SAS and disease activity.
While distress increases when disease is exacerbated
(Mikocka-Walus, Knowles, Keefer, & Graff, 2016), we
have demonstrated that IBD-specific anxiety is also fre-
quently present when disease is in remission (Reigada
et al., 2015). In addition, based on our previous work
(Reigada et al., 2011), we expected a significant, mod-
erate correlation between IBD-SAS and nondisease-
specific measures of anxiety and depressive symptoms.
Methods
The present cross-sectional study is nested within an
ongoing longitudinal, Internet-based study conducted
by the Crohn’s and Colitis Foundation of America
(CCFA) Partners Kids and Teens Registry. The CCFA
Kids and Teens registry is a large, geographically di-
verse Internet-based cohort of children and adolescents
diagnosed with IBD. Recruitment methods included e-
mails to the CCFA registry, social media, print adver-
tisements, word of mouth, and promotion at CCFA
chapter meetings and fundraising events. Children and
adolescents between the ages of 12 and 18 years, with a
self-reported diagnosis of IBD (Crohn’s disease [CD],
ulcerative colitis [UC], or indeterminate colitis) and
Internet access met the inclusion criteria for this study.
Between March 2014 and August 2016, all eligible
participants were offered the IBD-SAS at the time they
completed the primary CCFA Partners survey, which
included questions about participants’ demographics,
HRQoL, mental health, and disease functioning. Two
samples were collected to accomplish study aims. First,
Sample 1 (n¼141) was collected for the EFA. Next,
Sample 2 (n¼ 140) was collected for the CFA. The
study protocol was approved by the institutional review
board at the University of North Carolina, Chapel Hill,
NC, and Vanderbilt University, Nashville, TN.
Measures
All measures included in this study were completed by
adolescent participants. Symptoms of general anxiety
and depression were measured using the Patient-
Reported Outcome Measurement Information System
(PROMIS; Ader, 2007). The pediatric version of the
PROMIS is a modified version of the adult PROMIS
(Irwin et al., 2010) and measures physical, mental, and
social aspects of health using a Likert-type response
scale ranging from 1 Never to 5 Almost always. Each
domain was measured using the four-item short forms.
Scores for each domain are used to generate a T-score,
with an M of 50 and SD of 10. Criterion validity and
responsiveness of pediatric PROMIS have been demon-
strated among a pediatric IBD sample (Arvanitis et al.,
2016). For this study, internal consistency of PROMIS
items was good (a¼ 88) and excellent (a ¼ .91) on
anxiety and depression domain items, respectively.
IBD HRQoL was measured using the IMPACT-III
(Otley et al., 2002). This instrument contains 35 ques-
tions, on a five-point Likert scale, focusing on issues relat-
ing to the bowel, body image, functional/social
impairment, emotional impairment, tests/treatments, and
systematic impairment. The full measure has documented
construct validity and excellent reliability (a ¼ .92)
(Otley et al, 2006). Internal consistency of IMPACT
items in the current study sample was excellent (a ¼ .95).
IBD-specific anxiety was measured using the 20-
item IBD-SAS, which was described earlier.
Disease activity was measured using the Short
Crohn’s Disease Activity Index (SCDAI; Thia et al.,
2011) and the Pediatric Ulcerative Colitis Activity
Index (PUCAI; Turner et al., 2007) for CD and UC,
respectively. These indices have been validated and are
in wide use in both research and clinical care. The to-
tal sum scores of the SCDAI and PUCAI were trans-
formed into categorical activity: none (SCDAI <150;
PUCAI <10), mild (SCDAI 150–218; PUCAI 10–34),
moderate (SCDAI 219–450; PUCAI 35–65), and se-
vere (SCDAI¼ 450þ; PUCAI¼65þ).
Statistical Analyses
EFA was used as a first step in identification of the fac-
tor structure of the IBD-SAS in Sample 1 (n¼141), fol-
lowed by CFA in Sample 2 (n¼140). For the initial
EFA, factor structure of the IBD-SAS was conducted by
examining the fit of one-, two-, three-, and four-factor
models. We decided on the number of factors using
both empirical (i.e., goodness-of-fit indices) and theoret-
ical criteria (i.e., if the meaning of the factor is interpret-
able) and the practical/clinical utility of the factor (e.g.,
do at least two items load onto all factors, are any of
the items redundant). Good fit was indicated by SRMR
values close to .08 or below, RMSEA values close to
.06, CFI values close to .95 or greater. CFA proce-
dures were used to confirm superior model fit of empiri-
cal and clinically relevant models derived from the EFA.
All EFA and CFA analyses, except where indicated oth-
erwise, were conducted using Mplus, version 7.2
(Muthén & Muthén, 1998–2014). Maximum like-
lihood estimation was used for both EFA and CFA,
while geomin rotation was used for EFA. An item was
considered to load onto a parent factor if its standard-
ized loading was j.40j (Comrey & Lee, 1992). Items
with loadings above this threshold on two or more fac-
tors were considered to have cross-loaded.
Unstandardized Cronbach alpha coefficients were
used to estimate internal item consistency of the total
IBD-SAS and for each factor. Convergent validity of the
IBD-SAS was examined using a series of correlational
analyses (Pearson for continuous and Spearman for or-
dinal variables) with measures theoretically expected to
be moderately to strongly associated with IBD-specific
anxiety, including IBD HRQoL (IMPACT-III), general
(nonhealth focused) anxiety and depression (PROMIS),
and IBD severity (PUCAI/SCDAI). Following conven-
tion, a correlation between .40 and .59 was considered
“moderate,” between .60 and .79 was considered
“strong,” and >.80 was deemed “very strong” (Evans,
1996). SPSS Statistics software version 23 was used for
descriptive, reliability, and validity analyses.
Results
Participants
Combining Samples1 and 2, participants included 281
adolescents, ages 12–18 (M¼ 14.8, SD¼1.78) years;
51% were male. Most self-identified as Caucasian
(90%) and had a diagnosis of CD (79%). In total,
19% were diagnosed with IBD by the age of 10 years.
Based on self-reported IBD activity (current), 68%
(n¼ 192) were in remission, 18% (n¼50) had mild
activity, 10% (n¼ 28) had moderate activity, and
<1% (n¼1) had severe activity. Current corticoste-
roid treatment was reported by 11% (n¼ 30) and
more than half of the sample (n¼160, 57%) were on
biologic therapy to treat their disease. Mother educa-
tion level included less than high school (2%), high
school (6%), some college (15%), college (42%), and
graduate school (35%). Father education level in-
cluded less than high school (1%), high school (13%),
some college (16%), college (40%), and graduate
school (30%). The sample was geographically diverse
with participants residing in 40 U.S. states and 3 for-
eign countries. Participant characteristics by Sample 1
and Sample 2 are displayed in Table I.
Item Distributions
Table II displays item Ms and SDs for all IBD-SAS
questions. The means were close to the lower bound
of the 0–5 scale, ranging from .59 to 1.61. All items
had a positive skew. The overall mean of the 20-item
IBD-SAS across Samples 1 and 2 was 18.82
(SD¼ 18.94), with scores ranging between 0 and 75.
Exploratory Factor Analysis (Sample 1)
Comparison of fit and information indices suggested
the superiority of a four-factor model (see Table III for
factor loadings): v2(116)¼185.44, p< .001,
CFI¼ .97, RMSEA¼ .07 (CFit p¼ .08), SRMR¼ .03,
BIC¼ 7,068.45, followed by the three-factor model:
v2(133)¼273.76, p< .001, CFI¼ .84, RMSEA¼ .09
(CFit p< .001), SRMR¼ .04, BIC¼ 7,072.63; two-
factor model: v2(151)¼397.12, p< .001, CFI¼ .89,
RMSEA¼ .11 (CFit p< .001), SRMR¼ .06,
BIC¼ 7,106.92; and one-factor model:
v2(170)¼588.07, p< .001, CFI¼ .82, RMSEA¼ .13
(CFit p< .001), SRMR¼ .07, BIC¼7,203.85.
However, in the four-factor model, one factor was





Age M (SD) 14.81 (1.78) 14.52 (1.93)
Male %s 57 45
Caucasian % 92 86
Mother’s education M (SD) 4.01 (1.00) 4.04 (0.92)
Father’s education M (SD) 3.87 (1.03) 3.87 (1.05)
CD % 81 76
Age at diagnosis M (SD) 9.86 (3.13) 10.42 (3.21)
Note. Mother and father education scale is 1¼ less than high
school, 2¼high school, 3¼ some college, 4¼ college, and
5¼ graduate school.
CD¼Crohn’s disease.
composed of only two items. A similar problem was
present for the three-factor model.
Improvements to the four-factor model were made
in light of the imperfect fit of the model, modification
indices suggesting areas of ill-fit, and review of item
content. In total, two items were removed (from the
model, they were administered to all participants) and
the content of two items was changed on the basis of
Table II. IBD-SAS Item Ms and SDs
Item (range: 0–5) M (SD) Sample 1 M (SD) Sample 2 M (SD) Total
4. Having a flare up 0.94 (1.16) 1.26 (1.50) 1.10 (1.35)
5. Eating foods that may bother your IBD 1.11 (1.40) 1.30 (1.43) 1.20 (1.42)
6. Having pain 1.13 (1.30) 1.38 (1.50) 1.26 (1.41)
7. Having no control over your body 0.70 (1.07) 0.91 (1.34) 0.80 (1.21)
10. The side effects of IBD medicine (i.e., side effects are problems that the
IBD medicine might cause such as bloating and mood swings)
0.79 (1.20) 1.16 (1.51) 0.97 (1.37)
13. Missing taking your medication 0.59 (.94) 0.79 (1.16) 0.69 (1.06)
14. That your medication is not working 0.78 (1.13) 0.92 (1.42) 0.85 (1.28)
20. What will happen in the future because of IBD (i.e., needing surgery)? 1.15 (1.36) 1.61 (1.78) 1.38 (1.60)
12. Having to go to the hospital or visit your doctor 0.64 (1.08) 0.94 (1.28) 0.79 (1.19)
15. What your friends will think if you have IBD symptoms in front of them? 0.67 (1.12) 0.99 (1.42) 0.83 (1.29)
16. Leaving your house because of IBD symptoms 0.50 (.88) 0.75 (1.22) 0.62 (1.07)
17. Not being able to attend school because of IBD symptoms 0.75 (1.23) 1.08 (1.61) 0.91 (1.44)
18. Not being able to keep up or hang out with other kids because of IBD 0.70 (1.20) 1.06 (1.45) 0.88 (1.46)
19. Not doing well in physical activities because of IBD* 0.96 (1.40) 1.07 (1.53) 1.02 (146)
2. Having to go, and not having access to a bathroom 0.86 (1.16) 1.14 (1.35) 1.00 (1.27)
3. Having bloody stool 0.48 (.77) 0.80 (1.31) 0.64 (1.08)
8. Your height 0.87 (1.35) 0.86 (1.25) 0.86 (1.30)
9. Your weight 1.01 (1.35) 1.21 (1.52) 1.11 (1.43)
1. Having to go to the bathroom without warning 0.82 (1.02) 0.99 (1.28) 0.90 (1.16)
11. Having medical procedures (i.e., drawing blood, endoscopy) 0.81 (1.15) 1.21 (1.46) 1.01 (1.33)
Total 16.24 (17.35) 21.41 (20.14) 18.82 (18.94)
Note. IBD ¼ inflammatory bowel disease; IBD-SAS¼ IBD-Specific Anxiety Scale.
Table III. Standardized Factor Loadings for Four-Factor Model
Item Sample 1 Sample 2
F1 F2 F3 F4 F1 F2 F3 F4
4. Having a flare up .79 .06 .02 .06 .89 N/A N/A N/A
5. Eating foods that may bother your IBD .82 .04 .14 .01 .74 N/A N/A N/A
6. Having pain .82 .14 .12 .02 .81 N/A N/A N/A
7. Having no control over your body .68 .23 .06 .01 .82 N/A N/A N/A
10. The side effects of IBD medicine (i.e., side effects are problems that the
IBD medicine might cause such as bloating and mood swings)
.77 .21 .06 .26 .75 N/A N/A N/A
13. Missing taking your medication .31 .01 .05 .24 .40 N/A N/A N/A
14. That your medication is not working .69 .08 .02 .10 .80 N/A N/A N/A
20. What will happen in the future because of IBD (i.e., needing surgery)? .38 .29 .13 .15 .75 N/A N/A N/A
12. Having to go to the hospital or visit your doctor .12 .67 .18 .26 N/A .55 N/A N/A
15. What your friends will think if you have IBD symptoms in front of them? .18 .43 .24 .09 N/A .67 N/A N/A
16. Leaving your house because of IBD symptoms .22 .42 .36 .03 N/A .80 N/A N/A
17. Not being able to attend school because of IBD symptoms .11 .85 .05 .10 N/A .83 N/A N/A
18. Not being able to keep up or hang out with other kids because of IBD .01 .99 .03 .02 N/A .88 N/A N/A
19. Not doing well in physical activities because of IBDa .30 .59 .07 .16 N/A .85 N/A N/A
2. Having to go, and not having access to a bathroom .01 .05 .87 .02 N/A N/A .77 N/A
3. Having stool (bowel movements) containing bloodb .28 .11 .60 .10 N/A N/A .83 N/A
8. Your height .05 .01 .02 .87 N/A N/A N/A .40
9. Your weight .23 .21 .02 .48 N/A N/A N/A .94
1. Having to go to the bathroom without warning .26 .08 .61 .03 N/A N/A N/A N/A
11. Having medical procedures (i.e., drawing blood, endoscopy) .09 .44 .11 .21 N/A N/A N/A N/A
Note. Items in bold type were considered for factor loading interpretation. Factor 1¼F1; Factor 2¼F2; Factor 3¼F3; Factor 4¼F4;
IBD ¼ inflammatory bowel disease.
aIn Sample 1, this question read: “Not doing well in sports or dancing because of IBD.”
bIn Sample 1, this question read “Having bloody stool.”
these criteria. For example, a large, statistically signifi-
cant modification index suggested the addition of cor-
related residual terms between Items 1 and 2. Further
inspection of these items revealed that they were al-
most identical in content and, as a result, Item 1 was
removed. A similar rationale was used with Items 11
and 12. Several authors have cautioned against under-
taking model modifications purely on the basis of
modification indices, as these changes are less likely to
replicate in other samples. We have adopted this rec-
ommendation and provide practical and theoretical
justification for changes to the model from EFA to
CFA.
The text of Item 19 was changed from Samples 1 to
2 from “Not doing well in sports or dancing because
of IBD?” to “Not doing well in physical activities be-
cause of IBD?” to capture physical activity broadly
rather than specific activities. That is, children who
did not play sports or dance might answer this item
negatively, as originally worded, because it did not ap-
ply to them, when their IBD may affect their perfor-
mance in other physical activities in which they did
participate. Additionally, Item 3 was revised from
Samples 1 to 2 from “Having bloody stool” to
“Having stool (bowel movements) containing blood”
to increase clarity of wording. Item 1 was removed, as
it was judged to be too similar to Item 2 and, thus, re-
dundant. Item 11 was also removed as anxiety regard-
ing “Having medical procedures” is not, necessarily,
specific to IBD, and it was felt that this item might as-
sess more general anxiety related to medical proce-
dures, as opposed to anxiety related to IBD,
specifically. Finally, Items 13 and 20 were retained in
CFA, despite factor loadings <.40 cutoff, as both
items were deemed to be too clinically useful to drop
and loaded significantly in CFA. Using this slightly
amended and reduced item pool (now 18 items), the
four-, three-, and two-factor models were submitted
to CFA using Sample 2.
Confirmatory Factor Analysis (Sample 2)
CFA was conducted in an attempt to cross-validate
the EFA results and compare the three models of the
IBD-SAS. Comparison of fit and information indices
suggested the superiority of a four-factor model (see
Table III for factor loadings): v2(129)¼259.19,
p< .001, CFI¼ .92, RMSEA¼ .09 (CFit p< .001),
SRMR¼ .05, BIC¼7,599.34, when compared with
the three-factor model: v2(132)¼302.98, p< .001,
CFI¼ .90, RMSEA¼ .10 (CFit p< .001),
SRMR¼ .06, BIC¼7,628.29; and two-factor model:
v2(134)¼304.06, p< .001, CFI¼ .90, RMSEA¼ .10
(CFit p< .001), SRMR¼ .06, BIC¼ 7,619.49. Factor
1 of the IBD-SAS had high loadings on items that
assessed anxiety related to the occurrence of physical
symptoms of IBD, in particular pain and disease
relapse, and the treatment of IBD-related symptoms.
Factor 2 had high loadings on items that assessed anx-
iety associated with the impact of IBD on engaging in
social, physical, and school activities and general mo-
bility (e.g., leaving the house). Factor 3 seems to re-
flect anxiety related directly to bowel movements.
Factor 4 seems to reflect anxiety related to height and
weight disruption that can accompany IBD.
In Sample 2, all four factors of the IBD-SAS were
significantly correlated. Factors 2 and 4 are the most
highly intercorrelated, r (138)¼ .93, p< .001, fol-
lowed by Factors 1 and 2, r (138)¼ .82, p< .001; and
Factors 1 and 4, r (138)¼ .71, p< .001. Factors 2 and
3, r (138)¼ .53, p< .001, and Factors 3 and 4,
r (138)¼ .47, p< .001, are also highly intercorrelated.
Factors 1 and 3, however, are relatively orthogonal,
r (138)¼ .25, p¼ .02.
Reliability
The IBD-SAS showed excellent overall internal consis-
tency (20-item; Cronbach’s a¼ .95) and the deletion
of two items (1 and 11) did not improve the overall re-
liability of the scale (18-item; a¼ .95). Factors 1 and 2
demonstrated excellent internal reliability (a¼ .92 and
.91, respectively), while Factor 3 was acceptable
(a¼ .73) and Factor 4 fell within the questionable
range (a¼ .66).
External Validity
On the PROMIS, T-score means were 46.76
(SD¼ 10.26) and 43.58 (SD¼ 8.65), for anxiety and
depression, respectively. For the IMPACT, the M was
134.31 (SD¼18.94). As shown in Table IV, correla-
tion coefficients relevant to construct validation pro-
vide support that the IBD-SAS has convergent validity,
which is congruent with our hypotheses. The total 20-
item IBD-SAS, as well as Factor 1 and Factor 2, dis-
played a strong significant negative correlation with
IBD HRQoL, measured by the IMPACT. IBD-SAS
Factor 3 and Factor 4 had a negative moderate to
strong relationship with IBD HRQoL. Significant pos-
itive moderate to strong correlations were found be-
tween total score and factors of the IBD-SAS and
measures of anxiety, depression, and disease activity.
Discussion
The current study aimed to evaluate the factor struc-
ture and psychometric properties of the IBD-SAS in a
geographically diverse, nonclinical sample of 281
youth with IBD. Overall, the current study findings
provide preliminary reliability and validity support for
the IBD-SAS. Based on empirical and theoretical crite-
ria, we found that the IBD-SAS is best represented as a
four-factor model. Factor 1 captured worry related to
the physical symptoms and medical treatment of IBD.
Factor 2 had high loadings on worry items that were
associated with the impact of IBD on engaging in so-
cial and physical activities. Factor 3 related directly to
worry regarding bowel movements. Factor 4 included
worry related to height and weight disruption that can
accompany IBD. Of note, some factors within the
IBD-SAS were strongly correlated potentially suggest-
ing the subscales measure slightly similar manifesta-
tions of distress. Nonetheless, the four factors would
be useful if clinicians or clinical researchers have a
particular interest in assessing particular domains of
concern.
Findings regarding convergent validity of the IBD-
SAS are promising and provide preliminary support
for use of the IBD-SAS as a brief instrument to exam-
ine IBD-specific anxiety among adolescents diagnosed
with IBD. Congruent with our a priori hypothesis,
higher IBD-SAS scores were associated with lower
HRQoL. That is, youth with increased worries about
their IBD was likely to also reported having worsened
HRQoL. While disease severity (Otley et al., 2002;
Perrin et al., 2008; van der Have et al., 2014) and in-
ternalized conditions, including anxiety and depressive
symptoms (Loonen, Grootenhuis, Last, Koopman, &
Derkx, 2002) and psychiatric disorders (Gray,
Denson, Baldassano, & Hommel, 2011), are estab-
lished determinants of HRQoL, this report demon-
strates that IBD-specific anxiety may also be strongly
linked with HRQoL. Based on our sample, IBD-SAS
displayed a stronger association with HRQoL com-
pared with reports of general anxiety and depressive
symptoms, and disease activity, suggesting these two
constructs are more closely related supporting conver-
gent validity.
The strong association between IBD-SAS and
HRQoL, measured by the IMPACT-III, makes sense.
The 35-item IMPACT-III measures patient perception
of their health status and the impact of their illness on
their physical, social, and emotional functioning
(Otley et al., 2002). The IMPACT-III also includes six
questions that assess worry or feeling afraid pertaining
to disease exacerbation, health problems in the future,
presence of bloody stool, dating, and having an opera-
tion. However, there are several key differences be-
tween the IMPACT-III and IBD-SAS. The IBD-SAS
captures worry over a specific 2-week timeframe,
while the IMPACT-III does not specify a time frame.
Furthermore, the questions pertaining to worry on the
IMPACT-III are embedded in different domains, thus
not easily usable, nor is there psychometric data that
support the use of this measure in this manner. While
both the IMPACT-III and the IBD-SAS capture other
overlapping domains of interest including issues re-
lated to school, body image, medication, and pain to
name a few, the IBD-SAS captures how often one wor-
ries about these domains, while the IMPACT-III
assesses the degree to which youth perceive their IBD
gets in the way, bothers them and the associated feel-
ings (e.g., anger). Despite overlapping or convergent
domains of interest between IBD-specific anxiety and
HRQoL, there is a divergence between construct defi-
nitions and in measurement, which supports the dis-
tinction between these constructs.
The IBD-SAS was also strongly correlated with
measures of general, nonhealth, measures of anxiety
and depressive symptoms, and moderately associated
with disease activity. The strength of these relation-
ships was greater than expected. One study found that
a disease-specific measure was superior to generic
measures when examining quality of life in pediatric
IBD, as it had fewer ceiling effects and demonstrated
more variability in scores, suggesting greater sensitiv-
ity to change (Loonen et al., 2002). In a similar
fashion, this study provides preliminary support that
IBD-specific anxiety may be more closely associated
with HRQoL, and vice versa, compared with meas-
ures used to detect psychiatric symptoms and disor-
ders (e.g., social phobia, separation anxiety,
generalized anxiety, and depression disorders) that are
not necessarily circumscribed to disease adjustment.
Furthermore, disease activity and IBD-specific anxiety
are seemingly associated, but this relationship may be
Table IV. Correlations Between IBD-Specific Anxiety Total and Factors With IBD HRQoL, Anxiety, Depression, and Disease
Activity
Measure IBD-SAS F1 F2 F3 F4 IMPACT: HRQoL PROMIS: anxiety PROMIS: depression
IBD-SAS –
F1 .96 –
F2 .93 .84 –
F3 .74 .67 .63 –
F4 .61 .52 .50 .27 –
IMPACT: HRQoL .85 .81 .81 .61 .52 –
PROMIS: anxiety .65 .65 .58 .48 .40 .66 –
PROMIS: depression .67 .65 .61 .45 .49 .69 .68 –
Disease activity .55 .50 .52 .53 .26 .60 .35 .35
Note. All correlations significant at p < .01.
Factor 1¼F1; Factor 2¼F2; Factor 3¼F3; Factor 4¼F4; HRQoL¼health-related quality of life IBD ¼ inflammatory bowel disease;
IBD-SAS¼ IBD-Specific Anxiety Scale.
more complex as IBD-specific anxiety, by definition,
can be present in the absence of disease activity.
Strengths of our study include the use of a novel,
Internet-based cohort study, which allowed for a geo-
graphically diverse sample and decoupled survey ad-
ministration from clinic appointments. This is
important, as it avoided the potential for over-
estimation of anxiety when participants complete sur-
veys at the time of stressful clinical encounters. Some
limitations should be considered. All study data were
based on adolescent self-report. However, prior work
in our adult IBD cohort has demonstrated the validity
of patient self-report of diagnoses of CD and UC (con-
firmed by medical records in 96% of participants).
Furthermore, constructs such as anxiety are most ap-
propriately captured through self-report. The relative
homogeneity of the participant sample with regard to
race, parent education/socioeconomic status, and dis-
ease severity is another limitation. Although the cur-
rent sample is similar in demographic background to
other samples previously reported in the literature
(Gray et al., 2011; Mackner & Crandall, 2007), the
extent to which our findings are generalizable to all
adolescents with IBD, particularly those from lower
socioeconomic status or from an ethnic minority back-
ground, is unknown. Although participant disease se-
verity at the time of survey administration varied, the
majority of the adolescents fell within inactive or mild
disease severity ranges. Patients with severe disease
exacerbations may have been underrepresented in our
study; therefore, it is unknown to what extent these
findings generalize to patients during acute episodes of
disease inflammation. Future studies using recruitment
within medical settings may provide further informa-
tion regarding IBD-specific anxiety in this pediatric
condition. The variability in factor loadings between
Samples 1 and 2, while not uncommon, also under-
scores the importance of additional work replicating
the factor structure found in the current study. Finally,
correlations may be inflated because of common
method variance.
Future validation research for the IBD-SAS is re-
quired. The high correlation between factors could be
suggestive of a more complex, higher-order structure,
where Factors 2 and 4 form a second-order factor.
Future research should examine the possible interrela-
tionships between the four factors of this scale and
evaluate the potential for a higher-order structure. In
addition, the clinical utility of this measure would be
enhanced by establishing clinical cutoff scores and
minimal important differences. However, it is likely
that this measure will need to be used in tandem with
some marker of disease activity or health status. For
instance, when disease is in remission, elevated reports
of IBD-specific anxiety are likely unwarranted and
may signal adolescents that need more support or psy-
chological intervention (Reigada et al., 2014).
However, when disease is active, this measure may
also be useful. Carrying on with normal activities
when IBD symptoms are present (not severe) is typi-
cally an important goal for the long-term functioning
of children with IBD. Take for instance youth with fre-
quent and unpredictable bowel movements. If they re-
port high anxiety around bowel movements or
bathroom access, they may require additional guid-
ance to generate strategies (e.g., sit near the bathroom/
exit at restaurants and movies and download a rest-
room locator application on their smartphone) and
contingency plans (e.g., carry an emergency kit of wet
wipes, an extra set of underwear and pants, and a
plastic bag for soiled clothes) to increase confidence to
continue to engage in their regular activities.
Therefore, while the IBD-SAS can be used to detect
potential pediatric IBD patients in distress, follow-up
assessment and clinical judgment, which contextualize
health anxiety symptoms within a health status frame-
work, are recommended.
In conclusion, pediatric IBD patient medical care
has begun to extend beyond the assessment and treat-
ment of disease symptoms and management to incor-
porate disease-related psychosocial factors that may
also contribute to disease factors and quality of life.
Our study findings may have important implications
for clinicians and clinical researchers. Identifying
young people for whom IBD-specific anxiety is a clini-
cal issue is a critical first step. The IBD-SAS is a psy-
chometrically sound instrument that is brief and can
be completed in waiting rooms, during medical visits,
or between visits from the comfort of a patient’s own
home. Health providers should consider querying
patients directly about how disease-specific anxiety
may impact IBD management and quality of life.
When warranted, education and further support may
alleviate mild anxiety, and when appropriate, a refer-
ral to a mental health specialist should be provided.
Clinical researchers can use the IBD-SAS to investigate
factors that contribute to vulnerability for increased
disease-specific anxiety, whether these symptoms con-
tribute to disease processes (e.g., inflammation reoc-
currence), and the degree to which these symptoms
disrupt disease management as well as well-being and
functioning.
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